Thermo Fisher Scientific acquires Henogen, viral vector manufacturing business from Novasep
The business will be part of the Pharma Services business within the Laboratory Products and Services Segment.
Thermo Fisher Scientific and Groupe Novasep SAS (Novasep) announced that has completed the acquisition of Henogen, Novasep’s viral vector manufacturing business in for approximately €725 million in cash.
Novasep’s viral vector manufacturing business provides contract manufacturing services for vaccines and therapies to biotechnology companies and large biopharma customers. With two locations in Seneffe and Gosselies, , Novasep’s viral vector business offers more than 7,000 square meters of clinical and commercial manufacturing capacity. Founded more than 20 years ago, the business has approximately 400 employees with operational and technical expertise in a broad range of viral vector classes and estimated 2020 revenue of €80 million (or approximately ).
“Novasep’s viral vector business is an excellent strategic fit as continues to expand its capabilities for cell and gene vaccines and therapies globally. The addition of their manufacturing capabilities in complements our four development and manufacturing sites in . In addition, they bring an incredibly talented team with more than two decades of experience across a broad range of viral vectors. The combination will benefit our global customers seeking support and capacity in the region as well as European customers bringing new medicines to patients inside and outside of ,” said , Executive VP of .
, President and CEO of Novasep said, “ is an outstanding partner for our viral vector business and its future development. Our diverse customer base will benefit from the combination of our viral vector services capabilities with the scale and capabilities of . Our talented employees will bring deep expertise to an organization that shares our commitment to providing ground-breaking new medicines to patients.